參考文獻(xiàn)/References:
[1] Sadeghi M,Keshavarz-Fathi M,BaracosV,et al.Cancer cachexia:Diagnosis,assessment,and treatment[J].Crit Rev Oncol Hematol,2018,127(7):91-104.
[2] 段振東.中晚期胃癌患者體質(zhì)量指數(shù)與預(yù)后的相關(guān)性及中藥對胃癌患者生存質(zhì)量影響的臨床研究[D].天津:天津中醫(yī)藥大學(xué),2020.
[3] Lee W S,Lee J J,Liao A T,et al.Association between weight change during initial chemotherapy and clinical outcome in dogs with multicentric lymphoma[J].Vet Comp Oncol,2021,19(1):53-60.
[4] Morita Y,Sakaguchi T,Kitajima R,et al.Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer[J].BMC Cancer,2019,19(1):416.
[5] Argilés J M,Busquets S,Stemmler B,et al.Cancer cache xia:understanding the molecular basis[J].Nat Rev Cancer, 2014,14(11):754-762.
[6] Mondello P,Mian M,Aloisi C,et al.Cancer cachexia syndrome:pathogenesis,diagnosis,and new therapeutic options[J].Nutr Cancer,2015,67(1):12-26.
[7] Baracos V E,Martin L,Korc M,et al.Cancer-associated cachexia[J].Nat Rev Dis Primers,2018,4(1):17105.
[8] Anderson L J,Albrecht E D,Garcia J M.Erratum to:update on management of cancer-related cachexia[J].Curr Oncol Rep,2017,19(3):22.
[9] Zhang W L,Li N,Shen Q,et al.Establishment of a mouse model of cancer cachexia with spleen deficiency syndrome and the effects of atractylenolide I[J].Acta PharmacolSin,2020,41(2):237-248.
[10] 謝麗霞.基于ERK/MAPK通路探討芪藥雞金粥對化療后大鼠胃腸黏膜機(jī)械屏障損傷的保護(hù)作用[D].福州:福建中醫(yī)藥大學(xué),2015.
[11] 李天苗,李爽,米碩,等.健脾益氣方治療肺脾氣虛型非小細(xì)胞肺癌患者化療后癌因性疲乏的隨機(jī)對照研究[J].遼寧中醫(yī)雜志,2021,48(8):126-129.
[12] Touchefeu Y,Montassier E,Nieman K,et al.Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis-current evidence and potential clinical applications[J].Aliment Pharmacol Ther,2014,40(5):409-421.
[13] Wu J,Gan Y,Li M,et al.Patchouli alcohol attenuates 5-fluorouracil-induced intestinal mucositis via TLR2/MyD88/NF-kB pathway and regulation of microbiota[J].Biomed Pharmacother,2020,124(8):109883.
[14] 邵鐵娟,李海昌,謝志軍,等.基于脾主運(yùn)化理論探討脾虛濕困與腸道菌群紊亂的關(guān)系[J].中華中醫(yī)藥雜志,2014,29(12):3762-3765.
[15] 陳彬,梁芳,袁旭,等.健脾解毒方加減對脾氣虧虛證晚期結(jié)直腸癌化療患者腸道菌群及免疫功能的影響[J].中醫(yī)雜志,2020,61(5):423-427.
[16] 馬麗娟,王錫恩,張靜,等.益氣健脾方對宮頸癌同步放化療脾虛證候及免疫狀態(tài)的影響[J].中華中醫(yī)藥學(xué)刊,2020,38(10):236-239.
[17] 段永強(qiáng),成映霞,梁玉杰,等.益氣健脾中藥對脾虛大鼠骨骼肌組織中Ca2+/CaMKⅡ通路關(guān)鍵分子的干預(yù)作用[J].中藥材,2015,38(3):562-566.
[18] Xiong B,Qian H.Effects of Sijunzi decoction and Yupingfeng powder on expression of janus kinase-signal transducer and activator of transcription signal pathway in the brain of spleen-deficiency model rats[J].J Tradit Chin Med,2013, 33(1):78-84.
[19] Cario E,Gerken G,Podolsky D K.Toll-like receptor 2 con-trols mucosal inflammation by regulating epithelial barrier function[J].Gastroenterology,2007,132(4):1359-1374.
[20] Thorpe D W,Stringer A M,Gibson R J.Chemotherapy-induced mucositis: the role of the gastrointestinal microbiome and toll-like receptors[J].Exp Biol Med(Maywood), 2013,238(1):1-6.
[21] 胡瑩.益氣健脾化積方對GC化療的增效作用及對NF-κB信號通路調(diào)控的影響[D].南京:南京中醫(yī)藥大學(xué),2019.
[22] Garlanda C,Dinarello C A, Mantovani A.The interleukin-1 family: back to the future[J].Immunity,2013,39(6):1003-1018.
[23] Scheller J,Chalaris A,Schmidt-Arras D,et al.The pro-and anti-inflammatory properties of the cytokine interleukin-6[J].Biochim Biophys Acta,2011,1813(5):878-888.
[24] 汪耔璇.補(bǔ)中益氣湯聯(lián)合FOLFIRI化療方案治療晚期結(jié)直腸癌的臨床研究[D].南京:南京中醫(yī)藥大學(xué),2020.
[25] 董飛燕.補(bǔ)中益氣湯聯(lián)合腸內(nèi)營養(yǎng)支持對胃癌轉(zhuǎn)化化療患者營養(yǎng)狀況的臨床研究[D].杭州:浙江中醫(yī)藥大學(xué),2019.
[26] 梁建斌,劉剛.健脾燥濕湯在脾虛濕盛型大腸癌術(shù)后化療患者中的應(yīng)用[J].中國肛腸病雜志,2018,38(3):12-14.
[27] 張素芳,凌昌全,李柏,等.四生湯對脾虛證小鼠免疫功能和抗應(yīng)激能力的影響(英文)[J].中西醫(yī)結(jié)合學(xué)報(bào),2012,10(12):1465-1469.